Enoxaparin Sodium Price In China

• China: 24000 USD/Kg

 The price of enoxaparin sodium in China for Q2 2023 reached 24,000 USD/Kg in June.

The latest report by IMARC Group, titled “Enoxaparin Sodium Pricing Report 2024: Price Trend, Chart, Market Analysis, News, Demand, Historical and Forecast Data,” provides a thorough examination of the Prices. This report delves into the price of Enoxaparin Sodium globally, presenting a detailed analysis, along with informative Enoxaparin Sodium Price Chart. Through comprehensive Price analysis, the report sheds light on the key factors influencing these trend. Additionally, it includes historical data to offer context and depth to the current pricing landscape. The report also explores the Demand, analyzing how it impacts Industry dynamics. To aid in strategic planning, the price forecast section provides insights into price forecast, making this report an invaluable resource for industry stakeholders.

Report Offering:

• Monthly Updates: Annual Subscription
• Quarterly Updates: Annual Subscription
• Biannually Updates: Annual Subscription

The study delves into the factors affecting Enoxaparin Sodium price variations, including alterations in the cost of raw materials, the balance of supply and demand, geopolitical influences, and sector-specific developments.

The report also incorporates the most recent updates from the market, equipping stakeholders with the latest information on market fluctuations, regulatory modifications, and technological progress. It serves as an exhaustive resource for stakeholders, enhancing strategic planning and forecast capabilities.

Request For a Sample Copy of the Report: https://www.imarcgroup.com/enoxaparin-sodium-pricing-report/requestsample

Enoxaparin Sodium Price Trend Last Quarter

Enoxaparin sodium is a low molecular weight heparin (LMWH) used primarily as an anticoagulant to prevent and treat blood clots. It is derived from unfractionated heparin and works by inhibiting Factor Xa and thrombin, key components in the blood coagulation process. This medication is commonly prescribed for conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and in patients undergoing surgery or those with acute coronary syndrome to reduce the risk of clot formation. Enoxaparin is administered via subcutaneous injection and is favored for its predictable pharmacokinetics and lower risk of bleeding complications compared to unfractionated heparin. Additionally, it does not require routine laboratory monitoring, making it more convenient for both patients and healthcare providers.

Enoxaparin Sodium Industry Analysis

The global enoxaparin sodium market size reached US$ 3.8 Billion in 2023. By 2032, IMARC Group expects the market to reach US$ 9.2 Billion, at a projected CAGR of 10.30% during 2023-2032. The enoxaparin sodium market is experiencing significant growth, driven by various factors that influence its demand and utilization globally. Enoxaparin sodium, a low molecular weight heparin, is widely used as an anticoagulant in the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism, and in patients undergoing surgery.

One of the primary factors driving the market is the increasing prevalence of cardiovascular diseases and related conditions. With a rising global incidence of heart attacks, strokes, and other cardiovascular disorders, there is a heightened demand for anticoagulant therapies to manage and prevent these conditions. The aging population is another critical factor, as older adults are more susceptible to thrombotic events, necessitating the use of enoxaparin sodium for prophylactic and therapeutic purposes. Besides this, the growing awareness among healthcare professionals and patients about the benefits of low molecular weight heparins over traditional anticoagulants is propelling market growth.

Enoxaparin sodium offers advantages such as a predictable anticoagulant response, lower risk of heparin-induced thrombocytopenia, and ease of administration, making it a preferred choice in clinical settings. Furthermore, advancements in medical technology and healthcare infrastructure also play a crucial role in market growth. Improved diagnostic techniques and better healthcare facilities enable early detection and treatment of thrombotic disorders, boosting the use of enoxaparin sodium. Additionally, ongoing research and development activities are leading to the introduction of more effective formulations and delivery methods, enhancing patient compliance and outcomes.

Regional Price Analysis:

• Asia Pacific: China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand.
• Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal and Greece.
• North America: United States and Canada.
• Latin America: Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru
• Middle East & Africa: Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco.

Note: The current country list is selective, detailed insights into additional countries can be obtained for clients upon request.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145